Impacted by delayed semaglutide approvals in Canada
OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. The adjusted PAT stood at (Rs 472) million with adjusted EPS of (Rs 4.1), the Effective Interest Rate (EIR) was below 9 per cent, 200bps lower YoY.
Neeraj Sharma, CEO and MD, OneSource Specialty Pharma, said, “As previously anticipated, this has been a subdued quarter due to delays in customer approvals in Canada that have prolonged the transition from the MSA to the CSA phase. The inherent demand, however, remains intact with order book continuing to trend upwards. In our nascent biologics segment, we continue to witness strong interest, with another global biosimilar player onboarded and the funnel at a historic high.”
